Time with the appropriate fee, is being filed concurrently with this Amendment A.

A Supplemental Information Disclosure Statement is being filed concurrently herewith.

Please amend the subject application as follows:

In the Specification

On page 5, line 29, delete "mycocardial" and substitute --myocardial-- therefor.

On page 6, line 7, delete "mycocardial" and substitute --myocardial-- therefor.

On page 8, line 18, delete "1994)," insert --1994, now U.S. Patent No. 5,656,272),-- therefor.

On page 12, line 15, delete "1994)," insert --1994, now U.S. Patent No. 5,656,272),-- therefor.

On page 16, line 19, delete "c168A was deposited at the".

On page 16, delete lines 20-21.

On page 17, line 15, delete "1994)," insert --1994, now U.S. Patent No. 5,656,272),-- therefor.

On page 32, line 29, delete "1994)," insert --1994, now U.S. Patent No. 5,656,272),-- therefor.

In the Claims

Please cancel Claims 1-5 and 7 and amend Claims 6, 8-11, 13-16, 23, 28-33 and 35-37 as follows:

6. (Amended) A method of treating or preventing [a thrombotic disorder] thrombosis in an individual in need thereof comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the individual.

8. (Amended) A method of Claim 6 [7] wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.

9. (Amended) A method of Claim 8 wherein the antibody is selected from the group consisting of: a chimeric antibody, a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

10. (Amended) A method of Claim 9 wherein the antibody binds to one or more epitopes included in amino acid[s of hTNFα selected from the group consisting of] residues of about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNFα.

11. (Amended) A method of Claim 9 wherein the antibody [binds to the epitope of] competitively inhibits binding of TNFα to monoclonal antibody A2.

13. (Amended) A method of Claim 12 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNFα selected from the group consisting of] residues of about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNFα.

14. (Amended) A method of Claim 12 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNFα to monoclonal antibody cA2.

15. (Amended) A method of Claim 14 wherein the chimeric antibody is monoclonal antibody cA2.

16. (Amended) A method of Claim 6 [7] wherein the tumor necrosis factor antagonist is a receptor molecule, derivative or a fragment thereof which binds to tumor necrosis factor.

23. (Amended) A method of Claim 6 [7] wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis or tumor necrosis factor release.

28. (Amended) A method of Claim 6 [7] wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor receptor signalling.

29. (Amended) A method of decreasing plasma fibrinogen in an individual suffering from or at risk of thrombosis comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the individual.

30. (Amended) A method of Claim 29 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.

31. (Amended) A method of Claim 30 wherein the antibody is selected from the group consisting of: a chimeric antibody, a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

32. (Amended) A method of Claim 31 wherein the antibody binds to one or more epitopes included in amino acid[s of hTNFα selected from the group consisting of] residues of about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNFα.

33. (Amended) A method of Claim 32 wherein the antibody [binds to the epitope of] competitively inhibits binding of TNFα to monoclonal antibody A2.

35. (Amended) A method of Claim 34 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNFα selected from the group consisting of]